These findings suggest that the EBV-positive NPC cell lines were more sensitive to the inhibition of the canonical NF-κB pathway, which indicates that the drug could potentially be useful for clinically diagnosed EBV-positive NPC tumors. Here, NFKB1 is linked to nasopharyngeal carcinoma.